Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Olink is most often covered alongside Nautilus Biotechnology, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Olink, all published on February 27, 2026.
1 verified story tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Olink is most often covered alongside Nautilus Biotechnology, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Olink, all published on February 27, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Olink. Shared-story counts are live from our verified record — not editorial picks.
Seer (NASDAQ: SEER) reported quarterly earnings that exceeded analyst expectations by $0.03 per share, signaling resilience in the life sciences tools sector. The results highlight growing adoption of the company's Proteograph Product Suite as researchers increasingly prioritize high-resolution proteomics in drug discovery.
